Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone Quality of life: total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: lumacaftor vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Quality of life: total score · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) FEV1 (% predicted): relative change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor) Time to first pulmonary exacerbation · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual… Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo Quality of life: total score · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: lumacaftor vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo Time to first pulmonary exacerbation · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo Quality of life: total score · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo Time to first pulmonary exacerbation · adults with cystic fibrosis and with the F508del/MF genotype Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: cavosonstat vs placebo Quality of life: total score · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ High flow nasal cannula (HFNC) vs low flow nasal cannula (LFNC) Chronic lung disease (need for supplemental oxygen at 28 days of life) ‐ not measured · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1… High flow nasal cannula for respiratory support in term infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Telerehabilitation vs self‐training Clinical measures, such as reading speed or reading acuity at 6 months · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of… Telerehabilitation for people with low vision (2023) · Cochrane | no estimate extracted | NR | No studies |
Telerehabilitation vs self‐training Compliance at 6 months · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of… Telerehabilitation for people with low vision (2023) · Cochrane | no estimate extracted | NR | No studies |
Alemtuzumab 24 mg vs interferon beta‐1a New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Alemtuzumab for multiple sclerosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Alemtuzumab 12 mg vs interferon beta‐1a New or enlarging T2‐hyperintense lesions Assessed by: number of participants with new or enlarging T2‐hyperintense lesions · adults with relapsing–remitting multiple sclerosis Alemtuzumab for multiple sclerosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency of seizure · people with TSC Rapamycin and rapalogs for tuberous sclerosis complex (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Creatinine level · people with TSC Rapamycin and rapalogs for tuberous sclerosis complex (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR FEV1/FVC ratio · people with TSC Rapamycin and rapalogs for tuberous sclerosis complex (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR FEV1/FVC ratio · people with TSC Rapamycin and rapalogs for tuberous sclerosis complex (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR 50% reduction in tumour size · people with TSC Rapamycin and rapalogs for tuberous sclerosis complex (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs standard dressings therapy The proportion of pressure ulcers healed · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs the Healthpoint system Adverse events  · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT combined with internet‐plus home care vs standard care Outcomes  · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT combined with internet‐plus home care vs standard care Time to complete wound healing · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT combined with internet‐plus home care vs standard care Adverse events  · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs standard dressings therapy Time to complete wound healing · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs moist wound healing The proportion of pressure ulcers healed · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs moist wound healing Time to complete wound healing · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs moist wound healing Adverse events  · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs the Healthpoint system Outcomes  · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs the Healthpoint system Time to complete wound healing · adults with pressure ulcers Negative pressure wound therapy for treating pressure ulcers (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life – not reported · couples trying to conceive Timed intercourse for couples trying to conceive (2023) · Cochrane | no estimate extracted | NR | No studies |
Paracetamol vs placebo hours Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo to 7 days Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Mean time to resolution of pain Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Mean pain score at various time points Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Reconsultations Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Delayed antibiotic prescriptions Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs paracetamol Mean time to resolution of pain Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
Paracetamol vs placebo to 7 days Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
Paracetamol vs placebo Mean time to resolution of pain Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |
Paracetamol vs placebo Mean pain score at various time points Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in… (2023) · Cochrane | no estimate extracted | NR | No studies |